Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.

doi:10.1016/j.jtho.2022.08.015

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2022

Shi Yuankai, Wu Shiman, Wang Ke, Cang Shundong, Yao Wenxiu, Fan Yun, Wu Lin, Huang Meijuan, Li Xingya, Pan Yueyin, Yang Zhixiong, Zhu Bo, Chen Gongyan, Shi Jianhua, Sun Meili, Fang Jian, Wang Lijun, Chen Zhaohong, Liu Chunling, Li Jingzhang, Liu Jiwei, Sun Shenghua, Zhao Yanqiu, Guo Yanzhen, Meng Zili, Liu Zhefeng, Han Zhigang, Lu Hong, Ma Rui, Hu Sheng, Zhao Guofang, Liu Zheng, Xie Congying, Zhong Diansheng, Zhao Hui, Yu Huiqing, Zhang Longzhen, Bi Minghong, Yi Shanyong, Guo Shuliang, Yi Tienan, Li Wen, Lin Yingcheng, Shu Yongqian, Chen Zhendong, Guo Zhongliang, Greco Michael, Wang Tingting, Shen Haijiao

Abstract excerpt

INTRODUCTION: Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFR T790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC. METHODS: Patients with locally advanced or metastatic/recurrent NSCLC with confirmed EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 36049654
DOI: 10.1016/j.jtho.2022.08.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.PMID 36049654Read ↗

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.Semantic proximity Read ↗

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.Semantic proximity Read ↗

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.Semantic proximity Read ↗

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.Semantic proximity Read ↗

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.Semantic proximity Read ↗

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.Semantic proximity Read ↗

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.Semantic proximity Read ↗

Rezivertinib versus Gefitinib as First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 StudySemantic proximity Read ↗

Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression.Semantic proximity Read ↗

Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.Semantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.